The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the ... recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...

Get Instant Summarized Text (Gist) The FDA has approved Spravato (esketamine) nasal spray for adults with major depressive disorder unresponsive to at least two oral antidepressants. It is the ...

an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... communities about the difference between esketamine versus ketamine, and whether esketamine ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...